title: Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma.
authors.forename: M P
authors.initials: MP
authors.lastname: Brizzi
authors.forename: C M
authors.initials: CM
authors.lastname: Sculli
authors.forename: F
authors.initials: F
authors.lastname: Ragni
authors.forename: F
authors.initials: F
authors.lastname: Porpiglia
authors.forename: M
authors.initials: M
authors.lastname: Tampellini
authors.forename: G
authors.initials: G
authors.lastname: Gorzegno
authors.forename: A M
authors.initials: AM
authors.lastname: Priola
authors.forename: L
authors.initials: L
authors.lastname: Dogliotti
authors.forename: A
authors.initials: A
authors.lastname: Berruti
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary*; D002277:Carcinoma / Q000473:pathology*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D011859:Radiography; D001749:Urinary Bladder Neoplasms / Q000473:pathology*; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid